The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 2, 2010, Pages 208-219

  Mahtouk, Karène ^a   Tjin, Esther P M ^a   Spaargaren, Marcel ^a   Pals, Steven T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

B cell lymphoproliferative disorder; Diffuse large B cell lymphoma; HGF; MET; Multiple myeloma

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ADENOVIRUS VECTOR; AMG 102; ANTINEOPLASTIC AGENT; ARQ 197; BORTEZOMIB; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; JNJ 38877605; LENALIDOMIDE; MGCD 265; MITOGEN ACTIVATED PROTEIN KINASE; MK 2461; MONOCLONAL ANTIBODY 5D5; MONOCLONAL ANTIBODY DN30; MONOCLONAL ANTIBODY L2G7; MP 470; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PF 04217903; PRO 143966; PROTEIN NK2; PROTEIN NK4; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SGX 523; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 184; XL 880; ADAPTOR PROTEIN; AMUVATINIB; CABOZANTINIB; CRIZOTINIB; FORETINIB; HEPATOCYTE GROWTH FACTOR ANTIBODY; ONARTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ANTIBODY; PROTEIN GAB1; PROTEIN KINASE INHIBITOR; RILOTUMUMAB; SCATTER FACTOR RECEPTOR ANTIBODY; TIVANTINIB;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE DIFFERENTIATION; CANCER GENE THERAPY; CANCER GROWTH; CARCINOGENESIS; CLINICAL TRIAL; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; EMBRYO DEVELOPMENT; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; ADVANCED CANCER; BRAIN CANCER; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; ENZYME ACTIVATION; HEPATOCYTE GROWTH FACTOR GENE; HODGKIN DISEASE; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MARGINAL ZONE LYMPHOMA; MET GENE; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; ONCOGENE; PANCREAS CANCER; PHENOTYPE; PROSTATE CANCER; PROTEIN TARGETING; THYROID CANCER;

CELL DIFFERENTIATION; HEPATOCYTE GROWTH FACTOR; HUMANS; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 78649456121     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.07.006     Document Type: Review

References (151)

1. Uehara Y., Minowa O., Mori C., Shiota K., Kuno J., Noda T., Kitamura N. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995, 373:702-705.
2. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373:699-702.
3. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 2008, 7:504-516.
4. Jucker M., Gunther A., Gradl G., Fonatsch C., Krueger G., Diehl V., Tesch H. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk. Res. 1994, 18:7-16.
5. Derksen P.W., de Gorter D.J., Meijer H.P., Bende R.J., van Dijk M., Lokhorst H.M., Bloem A.C., Spaargaren M., Pals S.T. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003, 17:764-774.
6. Weimar I.S., de Jong D., Muller E.J., Nakamura T., van Gorp J.M., de Gast G.C., Gerritsen W.R. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 1997, 89:990-1000.
7. Stoker M., Gherardi E., Perryman M., Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327:239-242.
8. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., Tashiro K., Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443.
9. Miyazawa K., Tsubouchi H., Naka D., Takahashi K., Okigaki M., Arakaki N., Nakayama H., Hirono S., Sakiyama O., et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 1989, 163:967-973.
10. Naka D., Ishii T., Yoshiyama Y., Miyazawa K., Hara H., Hishida T., Kidamura N. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J. Biol. Chem. 1992, 267:20114-20119.
11. Shimomura T., Miyazawa K., Komiyama Y., Hiraoka H., Naka D., Morimoto Y., Kitamura N. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur. J. Biochem. 1995, 229:257-261.
12. Shimomura T., Kondo J., Ochiai M., Naka D., Miyazawa K., Morimoto Y., Kitamura N. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J. Biol. Chem. 1993, 268:22927-22932.
13. Cooper C.S., Park M., Blair D.G., Tainsky M.A., Huebner K., Croce C.M., Vande Woude G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311:29-33.
14. Park M., Dean M., Cooper C.S., Schmidt M., O'Brien S.J., Blair D.G., Vande Woude G.F. Mechanism of met oncogene activation. Cell 1986, 45:895-904.
15. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802-804.
16. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., Comoglio P.M. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989, 339:155-156.
17. Trusolino L., Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2002, 2:289-300.
18. Kong-Beltran M., Stamos J., Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004, 6:75-84.
19. Sachs M., Brohmann H., Zechner D., Muller T., Hulsken J., Walther I., Schaeper U., Birchmeier C., Birchmeier W. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 2000, 150:1375-1384.
20. Holgado-Madruga M., Emlet D.R., Moscatello D.K., Godwin A.K., Wong A.J. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 1996, 379:560-564.
21. Weidner K.M., Di Cesare S., Sachs M., Brinkmann V., Behrens J., Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996, 384:173-176.
22. Nguyen L., Holgado-Madruga M., Maroun C., Fixman E.D., Kamikura D., Fournier T., Charest A., Tremblay M.L., Wong A.J., Park M. Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356. J. Biol. Chem. 1997, 272:20811-20819.
23. Itoh M., Yoshida Y., Nishida K., Narimatsu M., Hibi M., Hirano T. Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol. Cell. Biol. 2000, 20:3695-3704.
24. Montesano R., Matsumoto K., Nakamura T., Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991, 67:901-908.
25. Gual P., Giordano S., Williams T.A., Rocchi S., Van Obberghen E., Comoglio P.M. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 2000, 19:1509-1518.
26. Furge K.A., Zhang Y.W., Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000, 19:5582-5589.
27. Comoglio P.M. Pathway specificity for Met signalling. Nat. Cell Biol. 2001, 3:E161-E162.
28. Maroun C.R., Moscatello D.K., Naujokas M.A., Holgado-Madruga M., Wong A.J., Park M. A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis. J. Biol. Chem. 1999, 274:31719-31726.
29. Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P., Giordano S., Graziani A., Panayotou G., Comoglio P.M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77:261-271.
30. Liu Y. Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am. J. Physiol. 1999, 277:F624-F633.
31. Fan S., Gao M., Meng Q., Laterra J.J., Symons M.H., Coniglio S., Pestell R.G., Goldberg I.D., Rosen E.M. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005, 24:1749-1766.
32. Moumen A., Patane S., Porras A., Dono R., Maina F. Met acts on Mdm2 via mTOR to signal cell survival during development. Development 2007, 134:1443-1451.
33. Maroun C.R., Naujokas M.A., Holgado-Madruga M., Wong A.J., Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 2000, 20:8513-8525.
34. Kodama A., Matozaki T., Fukuhara A., Kikyo M., Ichihashi M., Takai Y. Involvement of an SHP-2-Rho small G protein pathway in hepatocyte growth factor/scatter factor-induced cell scattering. Mol. Biol. Cell 2000, 11:2565-2575.
35. Koch A., Mancini A., El Bounkari O., Tamura T. The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 2005, 24:3436-3447.
36. Duan H.F., Qu C.K., Zhang Q.W., Yu W.M., Wang H., Wu C.T., Wang L.S. Shp-2 tyrosine phosphatase is required for hepatocyte growth factor-induced activation of sphingosine kinase and migration in embryonic fibroblasts. Cell. Signal. 2006, 18:2049-2055.
37. Hartmann G., Weidner K.M., Schwarz H., Birchmeier W. The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J. Biol. Chem. 1994, 269:21936-21939.
38. Fournier T.M., Kamikura D., Teng K., Park M. Branching tubulogenesis but not scatter of Madin-Darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. J. Biol. Chem. 1996, 271:22211-22217.
39. Sakkab D., Lewitzky M., Posern G., Schaeper U., Sachs M., Birchmeier W., Feller S.M. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J. Biol. Chem. 2000, 275:10772-10778.
40. Boccaccio C., Ando M., Tamagnone L., Bardelli A., Michieli P., Battistini C., Comoglio P.M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998, 391:285-288.
41. Schaeper U., Vogel R., Chmielowiec J., Huelsken J., Rosario M., Birchmeier W. Distinct requirements for Gab1 in Met and EGF receptor signaling in vivo. Proc. Natl. Acad. Sci. USA 2007, 104:15376-15381.
42. Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G., Barberis D., Tamagnone L., Comoglio P.M. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 2002, 4:720-724.
43. Orian-Rousseau V., Chen L., Sleeman J.P., Herrlich P., Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16:3074-3086.
44. Derksen P.W., Keehnen R.M., Evers L.M., van Oers M.H., Spaargaren M., Pals S.T. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002, 99:1405-1410.
45. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376:768-771.
46. Streit A., Stern C.D., Thery C., Ireland G.W., Aparicio S., Sharpe M.J., Gherardi E. A role for HGF/SF in neural induction and its expression in Hensen's node during gastrulation. Development 1995, 121:813-824.
47. Santos O.F., Barros E.J., Yang X.M., Matsumoto K., Nakamura T., Park M., Nigam S.K. Involvement of hepatocyte growth factor in kidney development. Dev. Biol. 1994, 163:525-529.
48. Boccaccio C., Comoglio P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 2006, 6:637-645.
49. Nusrat A., Parkos C.A., Bacarra A.E., Godowski P.J., Delp-Archer C., Rosen E.M., Madara J.L. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. J. Clin. Invest. 1994, 93:2056-2065.
50. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science 1997, 276:60-66.
51. Nakamura T., Mizuno S., Matsumoto K., Sawa Y., Matsuda H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 2000, 106:1511-1519.
52. Florquin S., Rouschop K.M. Reciprocal functions of hepatocyte growth factor and transforming growth factor-beta1 in the progression of renal diseases: a role for CD44?. Kidney Int. Suppl. 2003, S15-S20.
53. Kmiecik T.E., Keller J.R., Rosen E., Vande Woude G.F. Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood 1992, 80:2454-2457.
54. Takai K., Hara J., Matsumoto K., Hosoi G., Osugi Y., Tawa A., Okada S., Nakamura T. Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood 1997, 89:1560-1565.
55. Weimar I.S., Miranda N., Muller E.J., Hekman A., Kerst J.M., de Gast G.C., Gerritsen W.R. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp. Hematol. 1998, 26:885-894.
56. van der Voort R., Taher T.E., Derksen P.W., Spaargaren M., van der Neut R., Pals S.T. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv. Cancer Res. 2000, 79:39-90.
57. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 2003, 4:915-925.
58. van der Voort R., Taher T.E., Keehnen R.M., Smit L., Groenink M., Pals S.T. Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway. J. Exp. Med. 1997, 185:2121-2131.
59. Borset M., Hjorth-Hansen H., Seidel C., Sundan A., Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996, 88:3998-4004.
60. Teofili L., Di Febo A.L., Pierconti F., Maggiano N., Bendandi M., Rutella S., Cingolani A., Di Renzo N., Musto P., Pileri S., Leone G., Larocca L.M. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 2001, 97:1063-1069.
61. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.J., Walther M.M., Tsui L.C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L., Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S., Lerman M.I., Linehan W.M., Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 1997, 16:68-73.
62. Danilkovitch-Miagkova A., Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 2002, 109:863-867.
63. Wielenga V.J., van der Voort R., Taher T.E., Smit L., Beuling E.A., van Krimpen C., Spaargaren M., Pals S.T. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am. J. Pathol. 2000, 157:1563-1573.
64. Boon E.M., van der Neut R., van de Wetering M., Clevers H., Pals S.T. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 2002, 62:5126-5128.
65. L. Vermeulen, E.M.F. De Sousa, M. van der Heijden, K. Cameron, J.H. de Jong, T. Borovski, J.B. Tuynman, M. Todaro, C. Merz, H. Rodermond, M.R. Sprick, K. Kemper, D.J. Richel, G. Stassi and J.P. Medema, Wnt activity defines colon cancer stem cells and is regulated by the microenvironment, Nat. Cell. Biol. 12 (2010) 468-476.
66. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:10158-10163.
67. Wielenga V.J., Smits R., Korinek V., Smit L., Kielman M., Fodde R., Clevers H., Pals S.T. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 1999, 154:515-523.
68. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., Tjon-Pon-Fong M., Moerer P., van den Born M., Soete G., Pals S., Eilers M., Medema R., Clevers H. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
69. van der Voort R., Taher T.E., Wielenga V.J., Spaargaren M., Prevo R., Smit L., David G., Hartmann G., Gherardi E., Pals S.T. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J. Biol. Chem. 1999, 274:6499-6506.
70. Zeilstra J., Joosten S.P., Dokter M., Verwiel E., Spaargaren M., Pals S.T. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res. 2008, 68:3655-3661.
71. Klein U., Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 2008, 8:22-33.
72. Shapiro-Shelef M., Calame K. Regulation of plasma-cell development. Nat. Rev. Immunol. 2005, 5:230-242.
73. Tjin E.P., Bende R.J., Derksen P.W., van Huijstee A.P., Kataoka H., Spaargaren M., Pals S.T. Follicular dendritic cells catalyze hepatocyte growth factor (HGF) activation in the germinal center microenvironment by secreting the serine protease HGF activator. J. Immunol. 2005, 175:2807-2813.
74. van der Voort R., Keehnen R.M., Beuling E.A., Spaargaren M., Pals S.T. Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans. J. Exp. Med. 2000, 192:1115-1124.
75. Taher T.E., Tjin E.P., Beuling E.A., Borst J., Spaargaren M., Pals S.T. c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J. Immunol. 2002, 169:3793-3800.
76. Skibinski G., Skibinska A., James K. The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs. Immunology 2001, 102:506-514.
77. Koopman G., Parmentier H.K., Schuurman H.J., Newman W., Meijer C.J., Pals S.T. Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1/intercellular adhesion molecule 1 and very late antigen 4/vascular cell adhesion molecule 1 pathways. J. Exp. Med. 1991, 173:1297-1304.
78. Koopman G., Keehnen R.M., Lindhout E., Newman W., Shimizu Y., van Seventer G.A., de Groot C., Pals S.T. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J. Immunol. 1994, 152:3760-3767.
79. Tarte K., Zhan F., De Vos J., Klein B., Shaughnessy J. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003, 102:592-600.
80. Kyle R.A., Rajkumar S.V. Treatment of multiple myeloma: a comprehensive review. Clin. Lymphoma Myeloma 2009, 9:278-288.
81. Klein B., Tarte K., Jourdan M., Mathouk K., Moreaux J., Jourdan E., Legouffe E., De Vos J., Rossi J.F. Survival and proliferation factors of normal and malignant plasma cells. Int. J. Hematol. 2003, 78:106-113.
82. Seidel C., Borset M., Turesson I., Abildgaard N., Sundan A., Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998, 91:806-812.
83. Seidel C., Lenhoff S., Brabrand S., Anderson G., Standal T., Lanng-Nielsen J., Turesson I., Borset M., Waage A. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br. J. Haematol. 2002, 119:672-676.
84. Wader K.F., Fagerli U.M., Holt R.U., Stordal B., Borset M., Sundan A., Waage A. Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur. J. Haematol. 2008, 81:380-383.
85. Alexandrakis M.G., Passam F.H., Sfiridaki A., Kandidaki E., Roussou P., Kyriakou D.S. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am. J. Hematol. 2003, 72:229-233.
86. Pour L., Svachova H., Adam Z., Almasi M., Buresova L., Buchler T., Kovarova L., Nemec P., Penka M., Vorlicek J., Hajek R. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann. Hematol. 2010, 89:385-389.
87. Ludek P., Hana S., Zdenek A., Martina A., Dana K., Tomas B., Lucie K., Marta K., Jaroslav M., Miroslav P., Jiri V., Roman H. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur. J. Haematol. 2010, 84:332-336.
88. Pour L., Svachova H., Adam Z., Mikulkova Z., Buresova L., Kovarova L., Buchler T., Penka M., Vorlicek J., Hajek R. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010, 57:29-34.
89. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., Sanderson R., Yang Y., Wilson C., Zangari M., Anaissie E., Morris C., Muwalla F., van Rhee F., Fassas A., Crowley J., Tricot G., Barlogie B., Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99:1745-1757.
90. Tjin E.P., Derksen P.W., Kataoka H., Spaargaren M., Pals S.T. Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 2004, 104:2172-2175.
91. Hov H., Holt R.U., Ro T.B., Fagerli U.M., Hjorth-Hansen H., Baykov V., Christensen J.G., Waage A., Sundan A., Borset M. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin. Cancer Res. 2004, 10:6686-6694.
92. Stellrecht C.M., Phillip C.J., Cervantes-Gomez F., Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 2007, 67:9913-9920.
93. Phillip C.J., Stellrecht C.M., Nimmanapalli R., Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother. Pharmacol. 2009, 63:587-597.
94. Holt R.U., Baykov V., Ro T.B., Brabrand S., Waage A., Sundan A., Borset M. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 2005, 90:479-488.
95. Holt R.U., Fagerli U.M., Baykov V., Ro T.B., Hov H., Waage A., Sundan A., Borset M. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 2008, 93:619-622.
96. Vande Broek I., Asosingh K., Allegaert V., Leleu X., Facon T., Vanderkerken K., Van Camp B., Van Riet I. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004, 18:976-982.
97. Hov H., Tian E., Holien T., Holt R.U., Vatsveen T.K., Fagerli U.M., Waage A., Borset M., Sundan A. c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur. J. Haematol. 2009, 82:277-287.
98. Seidel C., Borset M., Hjertner O., Cao D., Abildgaard N., Hjorth-Hansen H., Sanderson R.D., Waage A., Sundan A. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000, 96:3139-3146.
99. Yang Y., Yaccoby S., Liu W., Langford J.K., Pumphrey C.Y., Theus A., Epstein J., Sanderson R.D. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002, 100:610-617.
100. Yang Y., MacLeod V., Dai Y., Khotskaya-Sample Y., Shriver Z., Venkataraman G., Sasisekharan R., Naggi A., Torri G., Casu B., Vlodavsky I., Suva L.J., Epstein J., Yaccoby S., Shaughnessy J.D., Barlogie B., Sanderson R.D. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007, 110:2041-2048.
101. Khotskaya Y.B., Dai Y., Ritchie J.P., MacLeod V., Yang Y., Zinn K., Sanderson R.D. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 2009, 284:26085-26095.
102. Reijmers R.M., Groen R.W., Rozemuller H., Kuil A., de Haan-Kramer A., Csikos T., Martens A.C., Spaargaren M., Pals S.T. Targeting EXT-1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 2010, 115:601-604.
103. Matsumoto K., Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. Front. Biosci. 2008, 13:1943-1951.
104. Andersen N.F., Standal T., Nielsen J.L., Heickendorff L., Borset M., Sorensen F.B., Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br. J. Haematol. 2005, 128:210-217.
105. Grano M., Galimi F., Zambonin G., Colucci S., Cottone E., Zallone A.Z., Comoglio P.M. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc. Natl. Acad. Sci. USA 1996, 93:7644-7648.
106. Hjertner O., Torgersen M.L., Seidel C., Hjorth-Hansen H., Waage A., Borset M., Sundan A. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999, 94:3883-3888.
107. G. Girasole, G. Passeri, R.L. Jilka and S.C. Manolagas, Interleukin-11 - a new cytokine critical for osteoclast development, J. Clin. Invest. 93 (1994) 1516-1524.
108. Standal T., Abildgaard N., Fagerli U.M., Stordal B., Hjertner O., Borset M., Sundan A. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007, 109:3024-3030.
109. Du W., Hattori Y., Yamada T., Matsumoto K., Nakamura T., Sagawa M., Otsuki T., Niikura T., Nukiwa T., Ikeda Y. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 2007, 109:3042-3049.
110. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 2005, 5:251-262.
111. Kawano R., Ohshima K., Karube K., Yamaguchi T., Kohno S., Suzumiya J., Kikuchi M., Tamura K. Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2004, 127:305-307.
112. Tjin E.P., Groen R.W., Vogelzang I., Derksen P.W., Klok M.D., Meijer H.P., van Eeden S., Pals S.T., Spaargaren M. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006, 107:760-768.
113. Capello D., Gaidano G., Gallicchio M., Gloghini A., Medico E., Vivenza D., Buonaiuto D., Fassone L., Avanzi G.C., Saglio G., Prat M., Carbone A. The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia 2000, 14:285-291.
114. Pons E., Uphoff C.C., Drexler H.G. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. Leuk. Res. 1998, 22:797-804.
115. Borset M., Lien E., Espevik T., Helseth E., Waage A., Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J. Biol. Chem. 1996, 271:24655-24661.
116. Elenitoba-Johnson K.S., Jenson S.D., Abbott R.T., Palais R.A., Bohling S.D., Lin Z., Tripp S., Shami P.J., Wang L.Y., Coupland R.W., Buckstein R., Perez-Ordonez B., Perkins S.L., Dube I.D., Lim M.S. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc. Natl. Acad. Sci. USA 2003, 100:7259-7264.
117. Hsiao L.T., Lin J.T., Yu I.T., Chiou T.J., Liu J.H., Yen C.C., Wang W.S., Chen P.M. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma. Eur. J. Haematol. 2003, 70:282-289.
118. Giles F.J., Vose J.M., Do K.A., Johnson M.M., Manshouri T., Bociek G., Bierman P.J., O'Brien S.M., Kantarjian H.M., Armitage J.O., Albitar M. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk. Res. 2004, 28:595-604.
119. Toschi L., Janne P.A. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin. Cancer Res. 2008, 14:5941-5946.
120. Eder J.P., Vande Woude G.F., Boerner S.A., LoRusso P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 2009, 15:2207-2214.
121. Chan A.M., Rubin J.S., Bottaro D.P., Hirschfield D.W., Chedid M., Aaronson S.A. Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 1991, 254:1382-1385.
122. Mazzone M., Basilico C., Cavassa S., Pennacchietti S., Risio M., Naldini L., Comoglio P.M., Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest. 2004, 114:1418-1432.
123. Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., Comoglio P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6:61-73.
124. Cao B., Su Y., Oskarsson M., Zhao P., Kort E.J., Fisher R.J., Wang L.M., Vande Woude G.F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 2001, 98:7443-7448.
125. Burgess T., Coxon A., Meyer S., Sun J., Rex K., Tsuruda T., Chen Q., Ho S.Y., Li L., Kaufman S., McDorman K., Cattley R.C., Elliott G., Zhang K., Feng X., Jia X.C., Green L., Radinsky R., Kendall R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006, 66:1721-1729.
126. Gordon M.S., Mendelson D.S., Sweeney C., Erbeck N., Patel R., Kakkar T., Yan L., Eckhardt S.G., Gore L. Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 2007, Vol 25, No. 18S:3551.
127. Kim K.J., Wang L., Su Y.C., Gillespie G.Y., Salhotra A., Lal B., Laterra J. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 2006, 12:1292-1298.
128. Martens T., Schmidt N.O., Eckerich C., Fillbrandt R., Merchant M., Schwall R., Westphal M., Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 2006, 12:6144-6152.
129. Petrelli A., Circosta P., Granziero L., Mazzone M., Pisacane A., Fenoglio S., Comoglio P.M., Giordano S. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. USA 2006, 103:5090-5095.
130. Christensen J.G., Burrows J., Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005, 225:1-26.
131. Sattler M., Pride Y.B., Ma P., Gramlich J.L., Chu S.C., Quinnan L.A., Shirazian S., Liang C., Podar K., Christensen J.G., Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003, 63:5462-5469.
132. Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., Le P., Chen J., Wang X., Ruslim L., Blake R., Lipson K.E., Ramphal J., Do S., Cui J.J., Cherrington J.M., Mendel D.B. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003, 63:7345-7355.
133. Arteaga C.L. HER3 and mutant EGFR meet MET. Nat. Med. 2007, 13:675-677.
134. Ross R., Srinivasan R., Vaishampayan U., Bukowski R., Rosenberg J., Eisenberg P., Logan T., Srinivas S., Stein M., Mueller T., Keer H. A phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). AACR Meeting Abstracts 2007, B249.
135. Eder J., Heath E., Appleman L., Shapiro G., Wang D., Malburg L., Zhu A., Leader T., Wolanski A., LoRusso P. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. Journal of Clinical Oncology 2007, Vol. 25, No. 18S (June 20 Supplement):3526.
136. Srinivasan R., Linehan W., Vaishampayan U., Logan T., Shankar S., Sherman L., Liu Y., Choueiri K. A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J. Clin. Oncol. 2009, 27:15s. (suppl; abstr 5103).
137. Jhawer M., Kindler H., Wainberg Z., Ford J., Kunz P., Tang L., McCallum S., Kallender H., Shah M. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study. J. Clin. Oncol. 2009, 27:15s. (suppl; abstr 4502).
138. Garcia A., Rosen L., Cunningham C., Nemunaitis J., Li C., Rulewski N., Dovholuk A., Savage R., Chan T., Bukowksi R., Mekhail T. Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. Journal of Clinical Oncology 2007, 3525.
139. Yap T., Harris D., Barriuso J., Wright W., Riisnaes R., Clark J., Ledaki I., Savage R., Chen T., De Bono J. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. J. Clin. Oncol. 2008, 26. (May 20 suppl; abstr 3584).
140. Mekhail T., Rich T., Rosen L., Chai F., Semic-Suka Z., Savage R., Senzer N. Final results: a dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J. Clin. Oncol. 2009, 27:15s. (suppl; abstr 3548).
141. Laux I., Goldman J., Just R., Brady K., Li J., Schwartz B., Savage R., Garmey E., Rosen L. Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. J. Clin. Oncol. 2009, 27:15s. (suppl; abstr 3549).
142. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., Yamazaki S., Alton G.R., Mroczkowski B., Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6:3314-3322.
143. Kwak E., Camidge D., Clark J., Shapiro G., Maki G., Ratain M., Solomon B., Bang Y., Ou S., Salgia R. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol. 2009, 27:15s. (suppl; abstr 3509).
144. Camacho L.H., Moulder S.L., LoRusso P.M., Blumenschein G.R., Bristow P.J., Kurzrock R., Fu S., Schlienger K., Bergstrom D.A. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. J. Clin. Oncol. 2008, 26. (May 20 suppl; abstr 14657).
145. Tolcher A., Berk G., Fine G., Choy G., Bearss D., Redkar S., Tibes R. MP470, a potent oral Rad51 suppressor is safe and tolerable in first-in-human study. AACR Meeting Abstracts, Apr 2008 2008, 4083.
146. Jessen K., Froning K., Felce J., Gutierrez A., Peterman M., Leonard S., Tang C., Huser N., Sperry S., Tran N., Sahly Y., Gessert S., Burley S., Reich S., Buchanan S. In vitro in vivo and anti-tumor activities of SGX523, a novel MET inhibitor. Abstract B233 2007, AACR/NCI/EORTC.
147. Perera T., Lavrijssen T., Janssens B., Geerts T., King P., Mevellec L., Cummings M., Lu T., Johnson D., Page M. JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models. AACR Meeting Abstracts, Apr 2008 2008, 4837.
148. Zou H., Li Q., Joseph L., Arango M., Burgess K., Yamazaki S., Parker M., Cui J., Cheng H., McTigue M., Los G., Bender S., Christensen J. PF-04217903, a novel selective c-Met kinase inhibitor with potent antitumor and anti-angiogenic properties in vitro and in vivo. AACR Meeting Abstracts, Apr 2008 2008, 4841.
149. Salgia R., Hong D., Camacho L., Ng C., Janisch L., Ratain M., Kurzrock R. A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Journal of Clinical Oncology 2007, Vol 25, No. 18S (June 20 Supplement):14031.
150. Salgia R., Sherman S., Hong D., Ng C., Frye J., Janisch L., Ratain M., Kurzrock R. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J. Clin. Oncol. 2008, 26. (May 20 suppl; abstr 3522).
151. Beaulieu N., Beaulieu C., Dupont I., Nguyen H., Chute I., Gravel S., Durand J., Robert M., Lefebvre S., Lu A., Dubay M., Rahil J., Isakovic L., Claridge S., Saavedra O., Raeppel S., Mannion M., Bernstein N., Zhan L., Gaudette F., Zhou N., Raeppel F., Granger M., Deziel R., Vaisburg A., Wang J., Besterman J., Macleod A., Maroun C. Preclinical development of MGCD265, a potent orally active c-Met/VEGFR multi-target kinase inhibitor. AACR Meeting Abstracts, Apr 2008 2008, 4838.